TCTC Holdings LLC grew its holdings in Medtronic plc (NYSE:MDT – Free Report) by 3.4% during the 4th quarter, HoldingsChannel.com reports. The firm owned 39,718 shares of the medical technology company’s stock after buying an additional 1,301 shares during the quarter. TCTC Holdings LLC’s holdings in Medtronic were worth $3,173,000 as of its most recent filing with the Securities & Exchange Commission.
Several other hedge funds and other institutional investors also recently modified their holdings of the business. State Street Corp increased its holdings in Medtronic by 0.9% during the 3rd quarter. State Street Corp now owns 60,731,367 shares of the medical technology company’s stock worth $5,509,155,000 after acquiring an additional 520,027 shares during the period. Raymond James Financial Inc. bought a new stake in Medtronic during the 4th quarter worth approximately $852,732,000. First Eagle Investment Management LLC increased its holdings in Medtronic by 0.3% during the 4th quarter. First Eagle Investment Management LLC now owns 9,792,200 shares of the medical technology company’s stock worth $782,201,000 after acquiring an additional 28,910 shares during the period. Pzena Investment Management LLC increased its holdings in Medtronic by 3.3% during the 3rd quarter. Pzena Investment Management LLC now owns 8,582,993 shares of the medical technology company’s stock worth $772,727,000 after acquiring an additional 275,870 shares during the period. Finally, Charles Schwab Investment Management Inc. increased its holdings in Medtronic by 1.7% during the 4th quarter. Charles Schwab Investment Management Inc. now owns 8,002,051 shares of the medical technology company’s stock worth $639,204,000 after acquiring an additional 134,647 shares during the period. Institutional investors own 82.06% of the company’s stock.
Insider Transactions at Medtronic
In other news, EVP Brett A. Wall sold 12,437 shares of Medtronic stock in a transaction that occurred on Friday, January 24th. The shares were sold at an average price of $90.00, for a total value of $1,119,330.00. Following the completion of the sale, the executive vice president now directly owns 40,979 shares in the company, valued at $3,688,110. The trade was a 23.28 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which is available through this link. Company insiders own 0.20% of the company’s stock.
Wall Street Analysts Forecast Growth
Get Our Latest Analysis on Medtronic
Medtronic Trading Up 0.9 %
Shares of NYSE MDT opened at $93.18 on Monday. The company has a debt-to-equity ratio of 0.48, a current ratio of 1.90 and a quick ratio of 1.39. The stock has a market cap of $119.51 billion, a P/E ratio of 28.32, a price-to-earnings-growth ratio of 2.22 and a beta of 0.80. Medtronic plc has a 1 year low of $75.96 and a 1 year high of $96.25. The firm has a 50-day moving average of $89.61 and a 200 day moving average of $87.95.
Medtronic (NYSE:MDT – Get Free Report) last issued its earnings results on Tuesday, February 18th. The medical technology company reported $1.39 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.36 by $0.03. The business had revenue of $8.29 billion during the quarter, compared to analysts’ expectations of $8.33 billion. Medtronic had a net margin of 12.83% and a return on equity of 14.07%. As a group, sell-side analysts expect that Medtronic plc will post 5.46 EPS for the current fiscal year.
Medtronic Announces Dividend
The company also recently announced a quarterly dividend, which will be paid on Friday, April 11th. Shareholders of record on Friday, March 28th will be issued a $0.70 dividend. The ex-dividend date is Friday, March 28th. This represents a $2.80 annualized dividend and a yield of 3.00%. Medtronic’s dividend payout ratio (DPR) is presently 85.11%.
About Medtronic
Medtronic plc develops, manufactures, and sells device-based medical therapies to healthcare systems, physicians, clinicians, and patients worldwide. Its Cardiovascular Portfolio segment offers implantable cardiac pacemakers, cardioverter defibrillators, and cardiac resynchronization therapy devices; cardiac ablation products; insertable cardiac monitor systems; TYRX products; and remote monitoring and patient-centered software.
See Also
- Five stocks we like better than Medtronic
- How Can Investors Benefit From After-Hours Trading
- How to Build the Ultimate Everything ETF Portfolio
- Diversification Can Smooth Returns And Mitigate Portfolio Risk
- Dutch Bros or Starbucks: Which Coffee Stock Has More Growth?
- What Percentage Gainers Tell Investors and Why They Don’t Tell the Whole Story
- 3 Stocks With High ROE and Market-Beating Growth Potential
Want to see what other hedge funds are holding MDT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Medtronic plc (NYSE:MDT – Free Report).
Receive News & Ratings for Medtronic Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Medtronic and related companies with MarketBeat.com's FREE daily email newsletter.